{"id":15029,"date":"2023-06-28T19:51:38","date_gmt":"2023-06-28T19:51:38","guid":{"rendered":"https:\/\/cpatacabamcdev.wpengine.com\/?page_id=15029"},"modified":"2025-10-15T13:59:17","modified_gmt":"2025-10-15T13:59:17","slug":"regle-15-competence-et-suivi-de-levolution-de-la-legislation-relative-au-privilege-du-secret-professionnel-boehringer-ingelheim-canada-ltd-c-pharmascience-inc","status":"publish","type":"page","link":"https:\/\/cpata-cabamc.ca\/fr\/votre-profession\/deontologie\/analyses-ethiques-et-recommandations-old\/regle-15-competence-et-suivi-de-levolution-de-la-legislation-relative-au-privilege-du-secret-professionnel-boehringer-ingelheim-canada-ltd-c-pharmascience-inc\/","title":{"rendered":"R\u00e8gle 1(5) \u2013 Comp\u00e9tence et suivi de l\u2019\u00e9volution de la l\u00e9gislation relative au privil\u00e8ge du secret professionnel \u2013 Boehringer Ingelheim (Canada) Ltd. c. Pharmascience Inc."},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"15029\" class=\"elementor elementor-15029 elementor-15000\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-ee97488 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"ee97488\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-75f71d4\" data-id=\"75f71d4\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-05ddc34 elementor-widget elementor-widget-text-editor\" data-id=\"05ddc34\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Une d\u00e9cision de la Cour f\u00e9d\u00e9rale du 21\u00a0avril\u00a02023 dans l\u2019affaire <em><a href=\"https:\/\/www.canlii.org\/en\/ca\/fct\/doc\/2023\/2023fc584\/2023fc584.html\" target=\"_blank\" rel=\"noopener\">Boehringer Ingelheim (Canada)\u00a0Ltd.\u00a0c. Pharmascience\u00a0Inc<\/a>. <\/em>a explor\u00e9 la signification et l\u2019applicabilit\u00e9 du privil\u00e8ge du secret professionnel des agent(e)s de brevets.<\/p><p>Les titulaires de permis ont l\u2019obligation \u00e9thique de suivre l\u2019\u00e9volution du droit en ce qui concerne leur profession, conform\u00e9ment \u00e0 la r\u00e8gle\u00a01(5) du Code de d\u00e9ontologie (le \u00ab\u00a0Code\u00a0\u00bb). La r\u00e8gle\u00a01(5) pr\u00e9voit aussi express\u00e9ment que les titulaires de permis doivent se tenir au courant de l\u2019\u00e9volution de la l\u00e9gislation relative au privil\u00e8ge du secret professionnel des agent(e)s de brevets et des agent(e)s de marques de commerce. L\u2019analyse qui suit met en \u00e9vidence certaines des cons\u00e9quences de cette d\u00e9cision de justice.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3e596e1 elementor-widget elementor-widget-heading\" data-id=\"3e596e1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Le sc\u00e9nario<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4282c17 elementor-widget elementor-widget-text-editor\" data-id=\"4282c17\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Dans l\u2019affaire <a href=\"https:\/\/www.canlii.org\/en\/ca\/fct\/doc\/2023\/2023fc584\/2023fc584.html\" target=\"_blank\" rel=\"noopener\"><em>Boehringer Ingelheim (Canada)\u00a0Ltd.\u00a0c. Pharmascience\u00a0Inc.<\/em><\/a>, les demanderesses, Boehringer Ingelheim (Canada)\u00a0Ltd. et\u00a0coll., ont caviard\u00e9 des renseignements avant de divulguer des documents \u00e0 la d\u00e9fenderesse, Pharmascience\u00a0Inc. Certains des caviardages ont \u00e9t\u00e9 effectu\u00e9s en vertu du privil\u00e8ge du secret professionnel des agent(e)s de brevets. Dans cette d\u00e9cision, la Cour a pris des d\u00e9cisions concernant l\u2019applicabilit\u00e9 du privil\u00e8ge du secret professionnel des agent(e)s de brevets.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9b51499 elementor-widget elementor-widget-heading\" data-id=\"9b51499\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Les r\u00e8gles<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-eef4248 elementor-widget elementor-widget-text-editor\" data-id=\"eef4248\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>La partie\u00a01 du Code de d\u00e9ontologie (le \u00ab\u00a0Code\u00a0\u00bb) \u00e9nonce les r\u00e8gles relatives \u00e0 la comp\u00e9tence. La r\u00e8gle\u00a01(5) dispose que<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-85c8af4 elementor-widget elementor-widget-text-editor\" data-id=\"85c8af4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"padding-left: 40px;\">L\u2019agent doit se tenir au courant des d\u00e9veloppements r\u00e9alis\u00e9s dans les secteurs du droit associ\u00e9s \u00e0 sa pratique en suivant de la formation continue. De plus, l\u2019agent doit se tenir au courant de l\u2019\u00e9volution de la l\u00e9gislation relative au privil\u00e8ge des agents de brevets et des agents de marques de commerce.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-684f676 elementor-widget elementor-widget-text-editor\" data-id=\"684f676\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Outre cette disposition expresse, la r\u00e8gle\u00a01(2) pr\u00e9voit que \u00ab\u00a0l\u2019agent ne respecte pas les normes de comp\u00e9tence professionnelle, si a) d\u2019une part, il existe des lacunes sur l\u2019un ou l\u2019autre des plans suivants\u00a0: (i) les connaissances, les habilet\u00e9s ou le jugement de l\u2019agent\u00a0\u00bb.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2431379 elementor-widget elementor-widget-heading\" data-id=\"2431379\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Conseils de CABAMC<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2a37442 elementor-widget elementor-widget-text-editor\" data-id=\"2a37442\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>L\u2019affaire <a href=\"https:\/\/www.canlii.org\/en\/ca\/fct\/doc\/2023\/2023fc584\/2023fc584.html\" target=\"_blank\" rel=\"noopener\"><em>Boehringer Ingelheim (Canada) Ltd. c. Pharmascience Inc.<\/em><\/a> a \u00e9t\u00e9 tranch\u00e9e par le juge adjoint Trent Horne \u2013 le m\u00eame juge qui a pris la d\u00e9cision concernant le privil\u00e8ge du secret professionnel des agent(e)s de brevets dans l\u2019affaire <em>Janssen Inc c. Sandoz Canada Inc, <\/em><a href=\"https:\/\/www.canlii.org\/fr\/ca\/cfpi\/doc\/2021\/2021cf1265\/2021cf1265.html\" target=\"_blank\" rel=\"noopener\">2021 CF 1265 <\/a>. Pour consulter un examen ant\u00e9rieur de l\u2019affaire Janssen, veuillez lire le bref <a href=\"https:\/\/cpata-cabamc.ca\/fr\/secret-professionnel-de-lagent-de-brevets-decision-de-la-cour-federale\/\" target=\"_blank\" rel=\"noopener\">r\u00e9sum\u00e9<\/a> et l\u2019<a href=\"https:\/\/cpata-cabamc.ca\/fr\/votre-profession\/deontologie\/analyses-ethiques-et-recommandations-old\/4-regle-15-competence-et-suivi-de-levolution-de-la-legislation-relative-au-privilege-le-debat-janssen\/\" target=\"_blank\" rel=\"noopener\">analyse \u00e9thique<\/a> du CABAMC.<\/p><p>L\u2019interpr\u00e9tation de ces deux d\u00e9cisions peut varier selon les personnes qui les lisent, mais le tribunal dans l\u2019affaire <a href=\"https:\/\/www.canlii.org\/en\/ca\/fct\/doc\/2023\/2023fc584\/2023fc584.html\" target=\"_blank\" rel=\"noopener\"><em>Boehringer Ingelheim (Canada) Ltd.<\/em> c. Pharmascience Inc.<\/a> a d\u00e9clar\u00e9 ceci [traduction] :<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1d1809c elementor-widget elementor-widget-text-editor\" data-id=\"1d1809c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li>\u00ab\u00a0Le texte du <a href=\"https:\/\/www.canlii.org\/fr\/ca\/legis\/lois\/lrc-1985-c-p-4\/derniere\/lrc-1985-c-p-4.html\" target=\"_blank\" rel=\"noopener\">paragraphe\u00a016.1(1)<\/a>(c) de la <a href=\"https:\/\/www.canlii.org\/fr\/ca\/legis\/lois\/lrc-1985-c-p-4\/derniere\/lrc-1985-c-p-4.html\" target=\"_blank\" rel=\"noopener\"><em>Loi sur les brevets<\/em><\/a> accorde un privil\u00e8ge \u00e0 toute affaire relative \u00e0 la protection d\u2019une invention. Il n\u2019est pas limit\u00e9 aux circonstances dans lesquelles une demande a \u00e9t\u00e9 d\u00e9pos\u00e9e ou est en instance\u00a0\u00bb (paragraphe\u00a050).<\/li><li>\u00ab\u00a0Je ne peux accepter l\u2019argument de Pharmascience selon lequel le d\u00e9p\u00f4t d\u2019une demande de brevet ou des instructions claires \u00e0 un(e) professionnel(le) des brevets d\u2019en r\u00e9diger une est une condition pr\u00e9alable n\u00e9cessaire [\u00e0 l\u2019application du privil\u00e8ge du secret professionnel des agent(e)s de brevet]\u00a0\u00bb (paragraphe\u00a052).<\/li><li>\u00ab\u00a0J\u2019ai des difficult\u00e9s particuli\u00e8res avec l\u2019argument de Pharmascience selon lequel lorsqu\u2019une demande de brevet est rejet\u00e9e par l\u2019OPIC, ou est volontairement retir\u00e9e par le(la) demandeur(-euse), le privil\u00e8ge du secret professionnel des agent(e)s de brevets ne s\u2019appliquerait pas. Je ne suis pas d\u2019accord avec Pharmascience pour dire qu\u2019il ne peut y avoir d\u2019\u201cinvention\u201d tant que l\u2019OPIC n\u2019a pas d\u00e9livr\u00e9 de brevet. Le texte de l\u2019article\u00a016.1 ne soutient pas une interpr\u00e9tation selon laquelle le privil\u00e8ge du secret professionnel peut \u00eatre acquis ou perdu en fonction de l\u2019existence ou du statut d\u2019une demande de brevet, ou qu\u2019une \u201cinvention\u201d n\u2019existe aux fins de cet article que si une demande de brevet a \u00e9t\u00e9 clairement demand\u00e9e, est en instance ou qu\u2019un brevet a \u00e9t\u00e9 d\u00e9livr\u00e9. J\u2019arrive \u00e0 la m\u00eame conclusion lorsque j\u2019examine l\u2019article\u00a016.1 dans le contexte de la <a href=\"https:\/\/www.canlii.org\/fr\/ca\/legis\/lois\/lrc-1985-c-p-4\/derniere\/lrc-1985-c-p-4.html\" target=\"_blank\" rel=\"noopener\"><em>Loi sur les brevets<\/em><\/a>. Le terme \u201c<a href=\"https:\/\/www.canlii.org\/fr\/ca\/legis\/lois\/lrc-1985-c-p-4\/derniere\/lrc-1985-c-p-4.html\" target=\"_blank\" rel=\"noopener\">invention<\/a>\u201d est d\u00e9fini \u00e0 l\u2019<a href=\"https:\/\/www.canlii.org\/fr\/ca\/legis\/lois\/lrc-1985-c-p-4\/derniere\/lrc-1985-c-p-4.html\" target=\"_blank\" rel=\"noopener\">article\u00a02<\/a> comme \u00e9tant \u201c[toute] r\u00e9alisation, tout proc\u00e9d\u00e9, toute machine, fabrication ou composition de mati\u00e8res, ainsi que tout perfectionnement de l\u2019un d\u2019eux, pr\u00e9sentant le caract\u00e8re de la nouveaut\u00e9 et de l\u2019utilit\u00e9\u201d. Le terme \u201cbrevet\u201d d\u00e9signe les \u201c[lettres] patentes couvrant une invention\u201d. Si la l\u00e9gislation avait voulu limiter le privil\u00e8ge du secret professionnel des agent(e)s de brevets aux seules demandes en cours ou aux seuls brevets d\u00e9livr\u00e9s, elle l\u2019aurait express\u00e9ment indiqu\u00e9\u00a0\u00bb (paragraphes\u00a054 \u00e0 55).<\/li><li>\u00ab\u00a0Limiter le privil\u00e8ge du secret professionnel des agent(e)s de brevets aux seules circonstances o\u00f9 un(e) client(e) charge un(e) agent(e) de brevets de d\u00e9poser et de tenir \u00e0 jour une demande pourrait dissuader quiconque de retenir les services d\u2019un(e) agent(e). Il y aurait une incertitude quant \u00e0 la question de savoir si le privil\u00e8ge s\u2019applique et pour combien de temps. Un(e) client(e) prudent(e) pourrait \u00eatre enclin(e) \u00e0 \u00e9viter l\u2019incertitude et \u00e0 conserver une invention en tant que secret commercial. Cela serait contraire aux objectifs centraux de la <a href=\"https:\/\/www.canlii.org\/fr\/ca\/legis\/lois\/lrc-1985-c-p-4\/derniere\/lrc-1985-c-p-4.html\" target=\"_blank\" rel=\"noopener\"><em>Loi sur les brevets<\/em><\/a> d\u00e9crits ci-dessus\u00a0\u00bb (paragraphe\u00a057). Il convient de noter que les deux principaux objectifs \u00e9nonc\u00e9s au paragraphe pr\u00e9c\u00e9dent \u00e9taient les suivants\u00a0: \u00ab\u00a0favoriser la recherche et le d\u00e9veloppement et encourager l\u2019activit\u00e9 \u00e9conomique en g\u00e9n\u00e9ral\u00a0\u00bb (paragraphe\u00a056).<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-dec1ec1 elementor-widget elementor-widget-text-editor\" data-id=\"dec1ec1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Dans l\u2019affaire <a href=\"https:\/\/www.canlii.org\/en\/ca\/fct\/doc\/2023\/2023fc584\/2023fc584.html\" target=\"_blank\" rel=\"noopener\"><em>Boehringer Ingelheim (Canada)\u00a0Ltd.\u00a0c. Pharmascience\u00a0Inc.<\/em><\/a>, le tribunal a pr\u00e9cis\u00e9 que le secret professionnel des agent(e)s ne d\u00e9pend pas du d\u00e9p\u00f4t d\u2019une demande ni du fait qu\u2019une demande soit finalement accept\u00e9e par l\u2019OPIC.<\/p><p>Les personnes titulaires de permis doivent savoir que, pour respecter les normes de comp\u00e9tence \u00e9nonc\u00e9es dans le Code, elles doivent maintenir leurs connaissances \u00e0 jour en suivant des \u00e9tudes et des formations. Les titulaires de permis devraient d\u00e9finir une strat\u00e9gie pour se tenir au courant de l\u2019\u00e9volution de la l\u00e9gislation, notamment en suivant diverses formes de perfectionnement professionnel continu, en participant \u00e0 des conf\u00e9rences, \u00e0 des d\u00eeners-conf\u00e9rences, \u00e0 des cours en ligne, \u00e0 des s\u00e9minaires ou \u00e0 des webinaires, en se joignant \u00e0 des groupes professionnels, en \u00e9crivant ou en lisant des blogues, en lisant des documents publi\u00e9s par le CABAMC et l\u2019IPIC. Les titulaires de permis peuvent \u00e9galement souhaiter acc\u00e9der \u00e0 des ressources publiques telles que <a href=\"https:\/\/www.canlii.org\/fr\/\" target=\"_blank\" rel=\"noopener\">CanLII<\/a>, qui fournit une base de donn\u00e9es consultable des d\u00e9cisions rendues par la Cour f\u00e9d\u00e9rale, l\u2019OPIC et d\u2019autres personnes qui prennent les d\u00e9cisions au Canada.<\/p><p>Les titulaires doivent \u00eatre conscient(e)s de leur obligation de se tenir au courant de l\u2019\u00e9volution de la jurisprudence relative \u00e0 leur profession, ainsi que de la l\u00e9gislation relative au privil\u00e8ge du secret professionnel des agent(e)s de brevets et des agent(e)s de marques de commerce en particulier.<\/p><p>En fin de compte, chaque titulaire de permis doit d\u00e9cider de la ligne de conduite \u00e0 adopter pour prot\u00e9ger les int\u00e9r\u00eats des client(e)s et respecter ses obligations professionnelles. Chaque cas est unique et il appartient \u00e0 la personne titulaire de permis d\u2019exercer son propre jugement professionnel.<\/p><p>Nous vous invitons \u00e0 communiquer avec nous si vous avez des questions sur la d\u00e9ontologie <a href=\"https:\/\/cpata-cabamc.ca\/fr\/votre-profession\/deontologie\/enquete-deontologique\/\" target=\"_blank\" rel=\"noopener\">en ligne<\/a>. Gr\u00e2ce au formulaire de demande de renseignements sur la d\u00e9ontologie, les sp\u00e9cialistes de la conduite professionnelle du CABAMC sont disponibles pour aider les titulaires de permis \u00e0 interpr\u00e9ter le Code dans le cadre du processus d\u2019\u00e9valuation des risques et d\u2019analyse \u00e9thique.\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Une d\u00e9cision de la Cour f\u00e9d\u00e9rale du 21\u00a0avril\u00a02023 dans l\u2019affaire Boehringer Ingelheim (Canada)\u00a0Ltd.\u00a0c. Pharmascience\u00a0Inc. a<\/p>\n","protected":false},"author":7,"featured_media":0,"parent":7202,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"folder":[],"class_list":["post-15029","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>R\u00e8gle 1(5) \u2013 Comp\u00e9tence et suivi de l\u2019\u00e9volution de la l\u00e9gislation relative au privil\u00e8ge du secret professionnel \u2013 Boehringer Ingelheim (Canada) Ltd. c. Pharmascience Inc. - CABAMC<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cpata-cabamc.ca\/fr\/votre-profession\/deontologie\/analyses-ethiques-et-recommandations-old\/regle-15-competence-et-suivi-de-levolution-de-la-legislation-relative-au-privilege-du-secret-professionnel-boehringer-ingelheim-canada-ltd-c-pharmascience-inc\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"R\u00e8gle 1(5) \u2013 Comp\u00e9tence et suivi de l\u2019\u00e9volution de la l\u00e9gislation relative au privil\u00e8ge du secret professionnel \u2013 Boehringer Ingelheim (Canada) Ltd. c. Pharmascience Inc. - CABAMC\" \/>\n<meta property=\"og:description\" content=\"Une d\u00e9cision de la Cour f\u00e9d\u00e9rale du 21\u00a0avril\u00a02023 dans l\u2019affaire Boehringer Ingelheim (Canada)\u00a0Ltd.\u00a0c. Pharmascience\u00a0Inc. a\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cpata-cabamc.ca\/fr\/votre-profession\/deontologie\/analyses-ethiques-et-recommandations-old\/regle-15-competence-et-suivi-de-levolution-de-la-legislation-relative-au-privilege-du-secret-professionnel-boehringer-ingelheim-canada-ltd-c-pharmascience-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"CABAMC\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-15T13:59:17+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cpata-cabamc.ca\/fr\/votre-profession\/deontologie\/analyses-ethiques-et-recommandations-old\/regle-15-competence-et-suivi-de-levolution-de-la-legislation-relative-au-privilege-du-secret-professionnel-boehringer-ingelheim-canada-ltd-c-pharmascience-inc\/\",\"url\":\"https:\/\/cpata-cabamc.ca\/fr\/votre-profession\/deontologie\/analyses-ethiques-et-recommandations-old\/regle-15-competence-et-suivi-de-levolution-de-la-legislation-relative-au-privilege-du-secret-professionnel-boehringer-ingelheim-canada-ltd-c-pharmascience-inc\/\",\"name\":\"R\u00e8gle 1(5) \u2013 Comp\u00e9tence et suivi de l\u2019\u00e9volution de la l\u00e9gislation relative au privil\u00e8ge du secret professionnel \u2013 Boehringer Ingelheim (Canada) Ltd. c. Pharmascience Inc. - CABAMC\",\"isPartOf\":{\"@id\":\"https:\/\/cpata-cabamc.ca\/fr\/#website\"},\"datePublished\":\"2023-06-28T19:51:38+00:00\",\"dateModified\":\"2025-10-15T13:59:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cpata-cabamc.ca\/fr\/votre-profession\/deontologie\/analyses-ethiques-et-recommandations-old\/regle-15-competence-et-suivi-de-levolution-de-la-legislation-relative-au-privilege-du-secret-professionnel-boehringer-ingelheim-canada-ltd-c-pharmascience-inc\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cpata-cabamc.ca\/fr\/votre-profession\/deontologie\/analyses-ethiques-et-recommandations-old\/regle-15-competence-et-suivi-de-levolution-de-la-legislation-relative-au-privilege-du-secret-professionnel-boehringer-ingelheim-canada-ltd-c-pharmascience-inc\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cpata-cabamc.ca\/fr\/votre-profession\/deontologie\/analyses-ethiques-et-recommandations-old\/regle-15-competence-et-suivi-de-levolution-de-la-legislation-relative-au-privilege-du-secret-professionnel-boehringer-ingelheim-canada-ltd-c-pharmascience-inc\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/cpata-cabamc.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Votre profession\",\"item\":\"https:\/\/cpata-cabamc.ca\/fr\/your-practice\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"D\u00e9ontologie\",\"item\":\"https:\/\/cpata-cabamc.ca\/fr\/your-practice\/professional-conduct\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Analyses \u00e9thiques et recommandations (OLD)\",\"item\":\"https:\/\/cpata-cabamc.ca\/fr\/?page_id=6974\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"R\u00e8gle 1(5) \u2013 Comp\u00e9tence et suivi de l\u2019\u00e9volution de la l\u00e9gislation relative au privil\u00e8ge du secret professionnel \u2013 Boehringer Ingelheim (Canada) Ltd. c. Pharmascience Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cpata-cabamc.ca\/fr\/#website\",\"url\":\"https:\/\/cpata-cabamc.ca\/fr\/\",\"name\":\"CABAMC\",\"description\":\"CABAMC\",\"publisher\":{\"@id\":\"https:\/\/cpata-cabamc.ca\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cpata-cabamc.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cpata-cabamc.ca\/fr\/#organization\",\"name\":\"CABAMC\",\"url\":\"https:\/\/cpata-cabamc.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/cpata-cabamc.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cpata-cabamc.ca\/wp-content\/uploads\/2021\/02\/Logo-Light-RGB.svg\",\"contentUrl\":\"https:\/\/cpata-cabamc.ca\/wp-content\/uploads\/2021\/02\/Logo-Light-RGB.svg\",\"caption\":\"CABAMC\"},\"image\":{\"@id\":\"https:\/\/cpata-cabamc.ca\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"R\u00e8gle 1(5) \u2013 Comp\u00e9tence et suivi de l\u2019\u00e9volution de la l\u00e9gislation relative au privil\u00e8ge du secret professionnel \u2013 Boehringer Ingelheim (Canada) Ltd. c. Pharmascience Inc. - CABAMC","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cpata-cabamc.ca\/fr\/votre-profession\/deontologie\/analyses-ethiques-et-recommandations-old\/regle-15-competence-et-suivi-de-levolution-de-la-legislation-relative-au-privilege-du-secret-professionnel-boehringer-ingelheim-canada-ltd-c-pharmascience-inc\/","og_locale":"fr_FR","og_type":"article","og_title":"R\u00e8gle 1(5) \u2013 Comp\u00e9tence et suivi de l\u2019\u00e9volution de la l\u00e9gislation relative au privil\u00e8ge du secret professionnel \u2013 Boehringer Ingelheim (Canada) Ltd. c. Pharmascience Inc. - CABAMC","og_description":"Une d\u00e9cision de la Cour f\u00e9d\u00e9rale du 21\u00a0avril\u00a02023 dans l\u2019affaire Boehringer Ingelheim (Canada)\u00a0Ltd.\u00a0c. Pharmascience\u00a0Inc. a","og_url":"https:\/\/cpata-cabamc.ca\/fr\/votre-profession\/deontologie\/analyses-ethiques-et-recommandations-old\/regle-15-competence-et-suivi-de-levolution-de-la-legislation-relative-au-privilege-du-secret-professionnel-boehringer-ingelheim-canada-ltd-c-pharmascience-inc\/","og_site_name":"CABAMC","article_modified_time":"2025-10-15T13:59:17+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cpata-cabamc.ca\/fr\/votre-profession\/deontologie\/analyses-ethiques-et-recommandations-old\/regle-15-competence-et-suivi-de-levolution-de-la-legislation-relative-au-privilege-du-secret-professionnel-boehringer-ingelheim-canada-ltd-c-pharmascience-inc\/","url":"https:\/\/cpata-cabamc.ca\/fr\/votre-profession\/deontologie\/analyses-ethiques-et-recommandations-old\/regle-15-competence-et-suivi-de-levolution-de-la-legislation-relative-au-privilege-du-secret-professionnel-boehringer-ingelheim-canada-ltd-c-pharmascience-inc\/","name":"R\u00e8gle 1(5) \u2013 Comp\u00e9tence et suivi de l\u2019\u00e9volution de la l\u00e9gislation relative au privil\u00e8ge du secret professionnel \u2013 Boehringer Ingelheim (Canada) Ltd. c. Pharmascience Inc. - CABAMC","isPartOf":{"@id":"https:\/\/cpata-cabamc.ca\/fr\/#website"},"datePublished":"2023-06-28T19:51:38+00:00","dateModified":"2025-10-15T13:59:17+00:00","breadcrumb":{"@id":"https:\/\/cpata-cabamc.ca\/fr\/votre-profession\/deontologie\/analyses-ethiques-et-recommandations-old\/regle-15-competence-et-suivi-de-levolution-de-la-legislation-relative-au-privilege-du-secret-professionnel-boehringer-ingelheim-canada-ltd-c-pharmascience-inc\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cpata-cabamc.ca\/fr\/votre-profession\/deontologie\/analyses-ethiques-et-recommandations-old\/regle-15-competence-et-suivi-de-levolution-de-la-legislation-relative-au-privilege-du-secret-professionnel-boehringer-ingelheim-canada-ltd-c-pharmascience-inc\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cpata-cabamc.ca\/fr\/votre-profession\/deontologie\/analyses-ethiques-et-recommandations-old\/regle-15-competence-et-suivi-de-levolution-de-la-legislation-relative-au-privilege-du-secret-professionnel-boehringer-ingelheim-canada-ltd-c-pharmascience-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/cpata-cabamc.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Votre profession","item":"https:\/\/cpata-cabamc.ca\/fr\/your-practice\/"},{"@type":"ListItem","position":3,"name":"D\u00e9ontologie","item":"https:\/\/cpata-cabamc.ca\/fr\/your-practice\/professional-conduct\/"},{"@type":"ListItem","position":4,"name":"Analyses \u00e9thiques et recommandations (OLD)","item":"https:\/\/cpata-cabamc.ca\/fr\/?page_id=6974"},{"@type":"ListItem","position":5,"name":"R\u00e8gle 1(5) \u2013 Comp\u00e9tence et suivi de l\u2019\u00e9volution de la l\u00e9gislation relative au privil\u00e8ge du secret professionnel \u2013 Boehringer Ingelheim (Canada) Ltd. c. Pharmascience Inc."}]},{"@type":"WebSite","@id":"https:\/\/cpata-cabamc.ca\/fr\/#website","url":"https:\/\/cpata-cabamc.ca\/fr\/","name":"CABAMC","description":"CABAMC","publisher":{"@id":"https:\/\/cpata-cabamc.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cpata-cabamc.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/cpata-cabamc.ca\/fr\/#organization","name":"CABAMC","url":"https:\/\/cpata-cabamc.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/cpata-cabamc.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/cpata-cabamc.ca\/wp-content\/uploads\/2021\/02\/Logo-Light-RGB.svg","contentUrl":"https:\/\/cpata-cabamc.ca\/wp-content\/uploads\/2021\/02\/Logo-Light-RGB.svg","caption":"CABAMC"},"image":{"@id":"https:\/\/cpata-cabamc.ca\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/cpata-cabamc.ca\/fr\/wp-json\/wp\/v2\/pages\/15029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cpata-cabamc.ca\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cpata-cabamc.ca\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cpata-cabamc.ca\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/cpata-cabamc.ca\/fr\/wp-json\/wp\/v2\/comments?post=15029"}],"version-history":[{"count":0,"href":"https:\/\/cpata-cabamc.ca\/fr\/wp-json\/wp\/v2\/pages\/15029\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/cpata-cabamc.ca\/fr\/wp-json\/wp\/v2\/pages\/7202"}],"wp:attachment":[{"href":"https:\/\/cpata-cabamc.ca\/fr\/wp-json\/wp\/v2\/media?parent=15029"}],"wp:term":[{"taxonomy":"folder","embeddable":true,"href":"https:\/\/cpata-cabamc.ca\/fr\/wp-json\/wp\/v2\/folder?post=15029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}